Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.